## LIST OF TABLES

<table>
<thead>
<tr>
<th>Table No</th>
<th>Contents</th>
<th>Page No</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>List of Chemicals</td>
<td>57</td>
</tr>
<tr>
<td>2.</td>
<td>List of Instruments</td>
<td>58</td>
</tr>
<tr>
<td>3.</td>
<td>IR Interpretation of Camptothecin</td>
<td>59</td>
</tr>
<tr>
<td>4.</td>
<td>Formulation of Polymeric Micelles Containing Camptothecin</td>
<td>62</td>
</tr>
<tr>
<td>5.</td>
<td>Formulation of Polymeric Micelles Containing Camptothecin</td>
<td>62</td>
</tr>
<tr>
<td>6.</td>
<td>Standard Graph of Camptothecin with PBS (pH 7.4)</td>
<td>73</td>
</tr>
<tr>
<td>7.</td>
<td>Particle Size and Polydispersity Index of Polymeric Micelles Containing Camptothecin</td>
<td>77</td>
</tr>
<tr>
<td>8.</td>
<td>Particle Size and Polydispersity Index of Polymeric Micelles Containing Camptothecin</td>
<td>77</td>
</tr>
<tr>
<td>9.</td>
<td>Encapsulation Efficiency of CPT Loaded PMs Using Different Drug: Polymer Ratio</td>
<td>82</td>
</tr>
<tr>
<td>10.</td>
<td>Encapsulation Efficiency of CPT Loaded PMs Using Different Drug: Polymer Ratio</td>
<td>83</td>
</tr>
<tr>
<td>11.</td>
<td>Critical Micellar Concentration of CPT-PMs Containing Chloroform: Acetonitrile</td>
<td>85</td>
</tr>
<tr>
<td>12.</td>
<td>Critical Micellar Concentration of CPT-PMs Containing Tetrahydro Furan</td>
<td>86</td>
</tr>
<tr>
<td>13.</td>
<td>In Vitro Release Profile of Camptothecin Solution</td>
<td>88</td>
</tr>
<tr>
<td>14.</td>
<td>In Vitro Release from Polymeric Micelles (F1) Containing Chloroform: Acetonitrile (PI, Drug: Polymer Ratio 1:2.5)</td>
<td>88</td>
</tr>
<tr>
<td>15.</td>
<td>In Vitro Release from Polymeric Micelles (F2) Containing Chloroform: Acetonitrile (PI, Drug: Polymer Ratio 1:5)</td>
<td>89</td>
</tr>
<tr>
<td>16.</td>
<td>In Vitro Release from Polymeric Micelles (F3) Containing Chloroform: Acetonitrile (PI, Drug: Polymer Ratio 1:12.5)</td>
<td>90</td>
</tr>
<tr>
<td>17.</td>
<td>In Vitro Release from Polymeric Micelles (F4) Containing Chloroform: Acetonitrile (PI, Drug: Polymer Ratio 1:25)</td>
<td>91</td>
</tr>
<tr>
<td>Table No</td>
<td>Contents</td>
<td>Page No</td>
</tr>
<tr>
<td>----------</td>
<td>--------------------------------------------------------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>18.</td>
<td><em>In Vitro</em> Release from Polymeric Micelles (F5) Containing Chloroform: Acetonitrile (PII, Drug: Polymer Ratio 1:2.5)</td>
<td>93</td>
</tr>
<tr>
<td>19.</td>
<td><em>In Vitro</em> Release from Polymeric Micelles (F6) Containing Chloroform: Acetonitrile (PII, Drug: Polymer Ratio 1:5)</td>
<td>94</td>
</tr>
<tr>
<td>20.</td>
<td><em>In Vitro</em> Release from Polymeric Micelles (F7) Containing Chloroform: Acetonitrile (PII, Drug: Polymer Ratio 1:12.5)</td>
<td>95</td>
</tr>
<tr>
<td>22.</td>
<td><em>In Vitro</em> Release from Polymeric Micelles (F9) Containing Tetrahydro Furan (PI, Drug: Polymer Ratio 1:5)</td>
<td>98</td>
</tr>
<tr>
<td>23.</td>
<td><em>In Vitro</em> Release from Polymeric Micelles (F10) Containing Tetrahydro Furan (PI, Drug: Polymer Ratio 1:12.5)</td>
<td>99</td>
</tr>
<tr>
<td>24.</td>
<td><em>In Vitro</em> Release from Polymeric Micelles (F11) Containing Tetrahydro Furan (PI, Drug: Polymer Ratio 1:25)</td>
<td>100</td>
</tr>
<tr>
<td>25.</td>
<td><em>In Vitro</em> Release from Polymeric Micelles (F12) Containing Tetrahydro Furan (PII, Drug: Polymer Ratio 1:5)</td>
<td>102</td>
</tr>
<tr>
<td>26.</td>
<td><em>In Vitro</em> Release from Polymeric Micelles (F13) Containing Tetrahydro Furan (PII, Drug: Polymer Ratio 1:12.5)</td>
<td>103</td>
</tr>
<tr>
<td>27.</td>
<td><em>In Vitro</em> Release from Polymeric Micelles (F14) Containing Tetrahydro Furan (PII, Drug: Polymer Ratio 1:25)</td>
<td>104</td>
</tr>
<tr>
<td>29.</td>
<td>Effect of Camptothecin Polymeric Micelles on the Hematological Parameters of Mice Bearing DLA</td>
<td>110</td>
</tr>
<tr>
<td>30.</td>
<td>Effect of Camptothecin Polymeric Micelles on the Life Span, Body Weight and Cancer Cell Count of Mice Bearing DLA</td>
<td>115</td>
</tr>
<tr>
<td>31.</td>
<td>Effect of Camptothecin Polymeric Micelles Formulation on Serum Lipid Profile</td>
<td>120</td>
</tr>
<tr>
<td>Table No</td>
<td>Contents</td>
<td>Page No</td>
</tr>
<tr>
<td>----------</td>
<td>---------------------------------------------------------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>32.</td>
<td>Effect of Camptothecin Polymeric Micelles Formulation on Solid Tumour Volume</td>
<td>123</td>
</tr>
<tr>
<td>33.</td>
<td>Standard Plot of Camptothecin in Spiked Plasma</td>
<td>127</td>
</tr>
<tr>
<td>34.</td>
<td>Tissue Distribution of Camptothecin Drug Solution in Various Organs</td>
<td>131</td>
</tr>
<tr>
<td>35.</td>
<td>Tissue Distribution of Camptothecin Polymeric Micelles (F4, PI, 1:25, chloroform: acetonitrile) in Various Organs</td>
<td>131</td>
</tr>
<tr>
<td>36.</td>
<td>Tissue Distribution of Camptothecin Polymeric Micelles (F8, PII, 1:25, chloroform: acetonitrile) in Various Organs</td>
<td>132</td>
</tr>
<tr>
<td>37.</td>
<td>Plasma Drug Concentration of Camptothecin Solution and Camptothecin Polymeric Micelles</td>
<td>135</td>
</tr>
<tr>
<td>38.</td>
<td>Pharmacokinetic Parameters of Camptothecin Solution and Camptothecin Polymeric Micelles</td>
<td>135</td>
</tr>
</tbody>
</table>